HIV, Lenacapavir and Gilead Sciences
2d
Barchart on MSNGilead Sciences - Leader in HIV MedicinesYour FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at ...
An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results